GLGS Glycogenesys Inc. (MM)

GlycoGenesys, Inc. (NASDAQ:GLGS), a biotechnology company focused on carbohydrate-based drug development, today announced that it will announce preliminary clinical data from its Phase I dose escalation trial the morning of September 8, 2005 and present at the Roth Capital Partners New York Conference later that morning. GlycoGenesys, Inc. CEO Bradley J. Carver, is scheduled to give the presentation. Presentation and Web Casting Information Roth Capital Partners New York Conference. The Westin New York at Time Square. Broadway II suite, 3rd Floor at 11:00 a.m. E.D.T. Presentation will be web cast live and will be available for replay. Please use the following link to access the web cast or its replay: http://www.wsw.com/webcast/roth6/glgs/ GlycoGenesys, Inc. GlycoGenesys, Inc. is a biotechnology company that develops and licenses compounds based on glycobiology. The Company's drug candidate GCS-100, a unique compound to treat cancer, has been evaluated in previous clinical trials at low dose levels in patients with colorectal, pancreatic and other solid tumors with stable disease and partial response documented. The Company currently is conducting a Phase I dose escalation trial to evaluate higher dose levels of GCS-100LE, a low ethanol formulation of GCS- 100, at Sharp Memorial Hospital, Clinical Oncology Research in San Diego, California and the Arizona Cancer Center in both Tucson and Scottsdale, Arizona. In addition, GCS-100LE is being evaluated in a Phase I/II trial for multiple myeloma. Further clinical trials are planned for 2005, 2006 and 2007. Further information is available on GlycoGenesys' web site: www.glycogenesys.com. Safe Harbor Statement Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, risks relating to raising sufficient capital to fund the Company's operations, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.